Background: Antineoplastic drugs are essential in the treatment of cancer; however, they are classified as hazardous due to their genotoxic, mutagenic, and carcinogenic properties. Healthcare professionals are at risk of exposure primarily through surface contamination. Despite international safety guidelines and technological innovations during the last decades, contamination remains a global occupational health challenge. Objective: This scoping review aims to identify and compare monitoring and detection methods, as well as cleaning and decontamination strategies, in relation to international occupational-safety standards. Methods: Following Arksey and O’Malley’s methodological framework and PRISMA-ScR reporting standards, the peer-reviewed literature and guidelines from 2000 to 2025 were reviewed. Studies were charted across three domains: contamination prevalence, monitoring/detection methods, and cleaning/decontamination effectiveness. Results: Evidence from twenty-two studies conducted in several countries worldwide demonstrated widespread surface contamination across hospital pharmacies, patient-care units, and outpatient facilities. Cyclophosphamide, ifosfamide, and methotrexate were the most frequently detected agents. LC—MS/MS wipe sampling remains the quantitative gold standard, while rapid immunoassay-based tools allow near real-time assessments but with reduced sensitivity. Cleaning protocols varied significantly: oxidizing and surfactant-based agents such as sodium hypochlorite and hydrogen peroxide achieved the highest removal rates (>90%) yet failed to eliminate residues completely. The included studies reported a wide range of monitoring, detection, and cleaning approaches used in healthcare settings. Conclusion: Surface contamination by antineoplastic drugs persists worldwide. Effective management requires harmonized contamination thresholds, validated cleaning strategies, adoption of rapid detection technologies, and continuous occupational surveillance.
Silva et al. (Sun,) studied this question.